Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced the promotions of Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO with immediate effect.
Key appointments strengthen Mission Therapeutics’ senior management team
Dr Paul Thompson (CSO) - pictured left
In his new role, Dr Thompson assumes responsibility for Mission’s discovery, validation and translational science activities, as well as biomarker research and target selection on novel DUBs.
Dr Thompson has ~18 years’ experience in translational research and early clinical development. He joined Mission as Medical Director for CNS in 2016, and in 2018 was promoted to Vice President of Clinical Development.
Previously, he has worked at ONO Pharma UK, where he was Clinical Science Director, and GlaxoSmithKline, where he led global project teams as Director of Discovery Medicine in Neurology, following earlier roles leading laboratory biomarker research and experimental medicine studies. Dr Thompson holds a PhD in Immuno- and Cell Biology from University College London and an MBiochem from the University of Oxford.
Dr Nick Edmunds (CTO) - right
Dr Edmunds assumes responsibility for Mission’s world-leading DUB platform and chemistry, in addition to exploratory toxicology and ADME activities.
With over 15 years’ pharmaceutical industry experience, Dr Edmunds has a track record in drug discovery and early clinical development. He joined Mission as a Senior Director in September 2018 from AstraZeneca and was promoted later that year to Vice President and Head of DUB Discovery.
At AstraZeneca Dr Edmunds held senior roles in Drug Safety and Metabolism, including Senior Director, Head of New Modalities and Director of Safety Pharmacology. Prior to that, he was a Research Fellow at Pfizer Global Research and Development, US, and the Cardiovascular Discipline Leader in Global Safety Pharmacology at Pfizer Global Research and Development, UK. Dr Edmunds holds a PhD from the Department of Pharmacology, University of Bath, and a BSc in Pharmacology from the University of Leeds.
Commenting on the appointments, Dr Anker Lundemose, CEO of Mission Therapeutics, said: “We are very pleased to be able to make these well-deserved promotions. Both Paul and Nick have already made substantial contributions to the advancement of Mission’s platform and pipeline. They will continue to play a pivotal role as the Company embarks upon the next exciting stage in its development, to continue progress of the AbbVie and Pfizer collaborations and bring our first-in-class USP30 inhibitor into the clinic.”
MISSION Therapeutics is a specialist pharmaceutical company whose aim is to translate new molecular understandings of human cell biology into drugs that will markedly improve the management of life-threatening diseases, particularly cancer.